^
    1d
    Comparison of postprocessing metrics in multimetabolic APT-weighted CEST and 2-deoxy-D-glucose-CEST-MRI for differentiating breast cancer subtypes in a murine model. (PubMed, Eur Radiol Exp)
    Advanced multimetabolic APTw-CEST and 2-deoxy-D-glucose-CEST postprocessing metrics allowed adequate preclinical murine BC subtyping. AREX showed potential for 2-deoxy-D-glucose-CEST in tumor characterization; however, APTw-CEST remains superior. MTRasym failed to distinguish between tumor subtypes in CEST-MRI.
    Clinical • Preclinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Akeega (abiraterone/niraparib)
    5d
    A brain-driven neural circuit contributes to tissue regeneration in joint cartilage. (PubMed, Ann Rheum Dis)
    Our findings unveil a brain-cartilage circuit that regulates cartilage regeneration, providing valuable insights into the inherent limitations of tissue regeneration and suggesting a promising treatment strategy for enhancing cartilage regeneration.
    Journal
    |
    ADRB2 (Adrenoceptor Beta 2) • PRG4 (Proteoglycan 4)
    |
    Akeega (abiraterone/niraparib)
    9d
    Characteristics of auditory event-related potential and prediction of IDH1 mutation in patients with insular glioma. (PubMed, Quant Imaging Med Surg)
    The IDH1-wt group showed higher amplitude of MMN evoked by novel stimulus at Fz and Cz and longer latency of the P300 component evoked by a deviant stimulus at Fz. The combination of AERP parameters yielded a more effective means to predict IDH1 mutation status in patients with insular glioma, which may provide guidance for the surgical intervention of this disease.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation • IDH wild-type
    |
    Akeega (abiraterone/niraparib)
    14d
    CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations (clinicaltrials.gov)
    P2, N=8, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting | N=30 --> 8 | Trial completion date: Mar 2027 --> Mar 2026 | Trial primary completion date: Mar 2027 --> Mar 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    SPOP (Speckle Type BTB/POZ Protein)
    |
    Akeega (abiraterone/niraparib)
    27d
    Effects of different intensities of electroacupuncture and manual acupuncture at "Shangjuxu" (ST37) on acute inflammatory visceral pain and their relationship with α7nAChR/PI3K/AKT signaling pathway (PubMed, Zhen Ci Yan Jiu)
    Both MA and 2 mA EA (not 3, 4, 6 mA EA) stimulation of ST37 have a similar analgesic effect in acute inflammatory visceral pain rats, which may be related to their function in suppressing the activities of α7nAChR/PI3K/AKT signaling pathway.
    Journal
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
    |
    Akeega (abiraterone/niraparib)
    1m
    CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations (clinicaltrials.gov)
    P2, N=30, Recruiting, Mayo Clinic | Trial completion date: Sep 2025 --> Mar 2027 | Trial primary completion date: Sep 2025 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    SPOP (Speckle Type BTB/POZ Protein)
    |
    Akeega (abiraterone/niraparib)
    12ms
    HARMONY: Niraparib, Abiraterone Acetate and Prednisone for MHSPC with Deleterious Homologous Recombination Repair Alterations (clinicaltrials.gov)
    P2, N=64, Recruiting, Qian Qin | Not yet recruiting --> Recruiting
    Enrollment open
    |
    docetaxel • Zejula (niraparib) • abiraterone acetate • Akeega (abiraterone/niraparib)
    1year
    CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations (clinicaltrials.gov)
    P2, N=30, Recruiting, Mayo Clinic | Trial completion date: Dec 2025 --> Sep 2025 | Trial primary completion date: Dec 2025 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    SPOP (Speckle Type BTB/POZ Protein)
    |
    SPOP mutation
    |
    Zejula (niraparib) • abiraterone acetate • Akeega (abiraterone/niraparib)
    1year
    CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations (clinicaltrials.gov)
    P2, N=30, Recruiting, Mayo Clinic | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    SPOP (Speckle Type BTB/POZ Protein)
    |
    SPOP mutation
    |
    Zejula (niraparib) • abiraterone acetate • Akeega (abiraterone/niraparib)
    over1year
    LUNAAR: 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Baptist Health South Florida | N=30 --> 0 | Trial completion date: Jul 2028 --> Oct 2028 | Initiation date: Jul 2024 --> Oct 2024 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2026 --> Oct 2026
    Enrollment change • Trial completion date • Trial initiation date • Trial withdrawal • Trial primary completion date • Metastases
    |
    Zejula (niraparib) • abiraterone acetate • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Akeega (abiraterone/niraparib)
    over1year
    STAMPEDE2: A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer (clinicaltrials.gov)
    P3, N=8000, Recruiting, University College, London | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    docetaxel • Zejula (niraparib) • Xtandi (enzalutamide) • abiraterone acetate • apalutamide • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Akeega (abiraterone/niraparib)
    over1year
    U.S. Food and Drug Administration (FDA) Approves FoundationOne Liquid CDx as a Companion Diagnostic for AKEEGA (niraparib and abiraterone acetate) for Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer (Businesswire)
    "Foundation Medicine, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne Liquid CDx to be used as a companion diagnostic for AKEEGA (niraparib and abiraterone acetate) from Janssen Biotech, Inc, a Johnson & Johnson company, the first and only FDA-approved dual-action tablet combining PARP inhibition and hormone therapy for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC)."
    FDA event
    |
    FoundationOne® Liquid CDx
    |
    Akeega (abiraterone/niraparib)